1. Long-term outcome and prognostic factors of single-dose Radioiodine Therapy in patients with Graves' disease
- Author
-
Feng-Chih Shen, Jung-Fu Chen, Chia-Jen Tsai, Chen-Kai Chou, Cheng-Feng Taso, Yi-Ting Yang, Chih-Min Chang, Pei-Wen Wang, Shih-Chen Tung, Ming-Chun Kuo, and Shao-Wen Weng
- Subjects
Adult ,medicine.medical_specialty ,Asia ,Goiter ,endocrine system diseases ,Graves' disease ,Taiwan ,Disease ,Tertiary referral hospital ,Iodine Radioisotopes ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,hemic and lymphatic diseases ,Radioiodine therapy ,medicine ,Humans ,Retrospective Studies ,Outcome ,Univariate analysis ,lcsh:R5-920 ,business.industry ,Retrospective cohort study ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Graves Disease ,Regimen ,Treatment Outcome ,Goiter size ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,business ,lcsh:Medicine (General) - Abstract
Background/purpose: Few studies exist investigating the effectiveness of radioiodine (RAI) therapy for hyperthyroidism patients in Asia. We herein investigated the real-world efficacy of single-dose RAI therapy in Taiwanese patients with Graves’ disease (GD). Methods: This is a retrospective study of 243 patients with GD recorded between 1989 and 2016 in a tertiary referral hospital. Eu- or hypothyroid after RAI therapy were defined as the successful group. Kaplan–Meier curve and cox-regression model were used for analysis of prognostic factors. Results: Of the 243 patients, 187 were females, with mean age of 46.9 ± 13.6 years. Most patients (63.8%) did not choose RAI as the first-line therapy. The median dose was 7 mCi, with a mean follow-up period of 107.1 ± 82.8 months. The overall success rate was 70.9%. Univariate analysis revealed calculated- or fixed-dose (P = 0.015), goiter size (P
- Published
- 2020